Hims & Hers Health, Inc.
New York Stock Exchange•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Andrew Dudum
- Full Time Employees
- 1,046
- Sector
- Consumer Defensive
- Industry
- Household & Personal Products
- Address
- 2269 Chestnut Street San Francisco CA United States of America 94123
- IPO Date
- Sep 13, 2019
- CIK
- 0001773751
- Website
- forhims.com
- Similar Companies
- Business
- Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
Company News
Hims & Hers: Driving Growth In Wellness
Why Hims & Hers Stock Jumped on Massive FDA News
Mizuho's Jared Holz on what Trump's FDA pick means for biotech innovation
Him & Hers Health Stock Doubled Options Bulls' Money
Bulls: Bet on a Rebound for This Telehealth Stock
Hims & Hers New Growth Category Is a Huge Surprise
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
What's Happening With HIMS Stock?
The FDA Can't Decide Whether Zepbound Is in Shortage. It's Good News for Hims & Hers Stock.
Hims & Hers Expands Nutrition Support to Fuel Customers' Weight Loss Journeys
Hims & Hers Health: Far From Dead, Even With Amazon's Threat Ahead
Hims & Hers Appoints Tenured Pharmaceutical, Regulatory, and Quality Experts to Key Leadership Positions
Hims & Hers Stock Is Down 30% This Week: Here's What Happened
Should You Buy Hims & Hers Stock on the Dip?
Hims & Hers: Revolutionizing Telehealth And Captivating Investors - Here's Why You Should Buy
Hims & Hers Health: The Amazon Curse Is Being Overstated
Hims & Hers stock tanks as Amazon debuts fixed pricing for hair-loss and erectile-dysfunction drugs
Hims & Hers' stock tumbles on Amazon's latest disruptive foray into healthcare
Amazon's push into telehealth knocks shares of Hims & Hers
Amazon launches fixed pricing to treat conditions like hair loss. Hims & Hers stock drops 15%